Skip to main content
. 2019 Mar 18;2019:7304140. doi: 10.1155/2019/7304140

Table 1.

Baseline characteristics of patients.

C (IA ≤ 5) L (IA 5-15.53) H (IA > 15.53) F value/chi-square p value
Age (year) 62.87 ± 10.58 63.64 ± 11.94 62.16 ± 10.27 0.228 0.797
Gender (M/F) 25/22 22/28 23/27 0.900d 0.638
Duration (month) 132 (120, 240) 174 (120, 240) 120 (72, 195) 5.134c 0.077
BMI (kg/m2) 24.90 ± 3.15 24.63 ± 3.66 24.63 ± 2.76 0.118 0.888
IA (%) 2.97 (1.76, 4.15) 8.80 (6.48, 11.76) 31.72 (21.80, 43.72)
Ln(IA) (%) 0.94 ± 0.58 2.16 ± 0.32a 3.42 ± 0.40ab 376.120 <0.001
HbA1c (%) 8.54 ± 1.62 8.43 ± 1.43 8.55 ± 1.48 0.095 0.910
Sqrt (C-p 0′) (ng/ml) 1.18 ± 0.46 1.11 ± 0.36 1.17 ± 0.42 0.532 0.588
Sqrt (C-p 120′) (ng/ml) 1.74 ± 0.56 1.73 ± 0.57 1.67 ± 0.65 0.181 0.835
C-p 0′ (-/+) 23/24 17/33 18/32 2.641 0.267
C-p 120′ (-/+) 8/39 7/43 6/44 0.504 0.777
Insulin dose 1 (U/kg) 0.30 (0.24, 0.37) 0.30 (0.23, 0.40) 0.28 (0.20, 0.36) 2.619 0.270
Insulin dose 2 (U/kg) 0.20 (0.13, 0.28) 0.22 (0.18, 0.33) 0.19 (0.16, 0.26) 3.864 0.145
Daily insulin dose (U/kg) 0.51 (0.40, 0.60) 0.53 (0.42, 0.73) 0.49 (0.35, 0.59) 2.850 0.241
Insulin/insulin analogue 14/33 12/38 13/37 0.427d 0.808
Oral drugs
 Met (-/+) 41/6 45/5 40/10 2.172d 0.338
 Aca (-/+) 38/9 40/10 42/8 0.295d 0.863
 Met+Aca (-/+) 43/4 48/2 44/6 2.218d 0.337

BMI: body mass index; IA: insulin antibody; Ln: base e logarithm; HbA1c: glycosylated hemoglobin A1c; Sqrt: square root; C-p: C-peptide; C-p 0′ (-): C-p 0′ ≤ 1.10 ng/ml; C-p 0′ (+): C-p 0′ > 1.10 ng/ml; C-p 120′ (-): C-p 120′ ≤ 1.10 ng/ml; C-p 120′ (+): C-p 120′ > 1.10 ng/ml; insulin dose 1: insulin dose before breakfast; insulin dose 2: insulin dose before dinner; Met: metformin; Aca: acarbose. aCompared with the C group (p < 0.05); bcompared with the L group (p < 0.05); cnonparametric test; dChi-square test. Data were presented as mean ± SD or median (25th, 75th percentile).